You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

24 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jul 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
ODB - General Benefit
    chlorambucil
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    prednisone
Jul 2019
Guidelines and Advice
Status: Archived
ID: CED 15
Nov 2009
Guidelines and Advice
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL), 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - Non-Hodgkin's Low Grade, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL), 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    chlorambucil
ODB - General Benefit
    prednisone
May 2019
Drug
Other Name(s): Leukeran®
Nov 2024
Drug
Other Name(s): Rituxan® SC
Updated
Apr 2025
Drug
Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™
Updated
Apr 2025
Drug
Other Name(s): Procytox®
Oct 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    chlorambucil
Dec 2018

Pages